Hikal (HIKAL) — Annual Report

📢 Key Event
Hikal Ltd reported FY 2025-26 revenue of INR 17,126 million with EBITDA margin of 13.6% and net loss of INR 487 million, driven by exceptional charges and US FDA regulatory impacts.

🔄 What Changed
Net loss of INR 487 million (vs. profit of INR 909 million previous year); EBITDA margin declined to 13.6% (from prior year); revenue decreased 7.91% YoY; net debt to equity improved to 0.56 from 0.59; interest cost reduced to INR 621 million from INR 752 million

🔮 What's Next
Target INR 500+ crore Personal Care revenue by 2029-30; EBITDA growth expected through capacity expansion; continued focus on CDMO partnerships and regulatory compliance; no specific future revenue targets provided

💡 Investor Takeaway
Hikal Ltd faces near-term profitability pressures from regulatory and exceptional items but maintains strategic momentum in high-value segments with strong ESG credentials and long-term growth targets.

Hikal Ltd reported FY 2025-26 revenue of INR 17,126 million with EBITDA margin of 13.6% and net loss of INR 487 million, driven by exceptional charges and US FDA regulatory impacts. The company achieved EcoVadis Gold rating, 78% renewable energy use, and zero fatalities, while advancing its Pinnacle 2.0 transformation with new Personal Care investments targeting INR 500+ crore by 2029-30. Strategic focus remains on high-value segments like pharmaceuticals and crop protection amid global industry growth.

📄 View Original Announcement (PDF)

📊 Stock Analysis — HIKAL ✨ Ask AI About This

About Hikal Ltd (HIKAL)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹2,487.59 Cr ROE: -2.7% ROCE: 0.1% Div Yield: 0.30%

View full HIKAL stock details →

📡 Get AI alerts when HIKAL files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track HIKAL — Free

💡 Ask AI about this filing

"What is the timeline for commissioning the remaining two new production lines at Panoli to achieve INR 500+ crore Personal Care revenue target by 2029-30?" "How will the company address US FDA regulatory challenges impacting its pharmaceutical segment revenue?" "What specific cost reduction initiatives are planned to improve EBITDA margins beyond current capacity utilization levels?"

Ask AI Free →

📊 More HIKAL filings

See all HIKAL filings →

🔥 Also filed on 31 August 2026

523896 AVI Products India Ltd Annual Report JKIL J Kumar Infraprojects Ltd Annual Report 514470 Winsome Textile Industries Ltd Annual Report ARKADE Arkade Developers Ltd Annual Report DCBBANK DCB Bank Ltd Corporate Action SIGMA Sigma Solve Ltd Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when HIKAL files new disclosures

Track HIKAL filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track HIKAL — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd